SCHEMBL9538450

SCHEMBL9538450

CCCCCCCCC(C)OC(=O)NC(C)(Cc1ccc2ccccc2n1)C(=O)NC(CO)Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LPAR1 Q92633 1/20 0.39
LPAR3 Q9UBY5 1/20 0.39
CTSK P43235 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSH P09668 1/20 0.39
TACR3 P29371 5/20 0.39
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
CYSLTR2 Q9NS75 3/20 0.36
CYSLTR1 Q9Y271 3/20 0.36
CYP3A4 P08684 1/20 0.36
MAPK1 P28482 1/20 0.36
TACR1 P25103 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9540182 0.84 KDM4E (0.41) KDM4EKMT2AL3MBTL1CTSKCTSL
SCHEMBL9538882 0.80 GABRA1 (0.41) KDM4EKMT2AL3MBTL1TACR3CYP3A4
SCHEMBL9540664 0.79 TACR1 (0.55) TACR3TACR1
SCHEMBL9540669 0.79 TACR1 (0.55) TACR3TACR1
SCHEMBL9538034 0.69 TACR3 (0.54) TACR3TACR1
SCHEMBL9338635 0.69 TACR1 (0.55) TACR3TACR1
SCHEMBL9399661 0.69 CYP3A4 (0.68) KDM4EKMT2ACYSLTR2CYSLTR1CYP3A4
SCHEMBL9539374 0.68 TACR3 (0.45) KDM4EKMT2AL3MBTL1LPAR1LPAR3
SCHEMBL7668995 0.66 MAPK1 (0.45) KMT2ACYP3A4MAPK1ALDH1A1
SCHEMBL9399648 0.66 CYP1A2 (0.48) KDM4EKMT2ACYSLTR2CYSLTR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1993003721-A1 CHOLECYSTOKININ ANTAGONISTS USEFUL FOR TREATING DEPRESSION WARNER-LAMBERT COMPANY (US) 1993-03-04 WO disclosed